Cytotoxic lymphocyte microRNAs as prospective biomarkers for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.

BACKGROUND Immune dysfunction associated with a disease often has a molecular basis. A novel group of molecules known as microRNAs (miRNAs) have been associated with suppression of translational processes involved in cellular development and proliferation, protein secretion, apoptosis, immune function and inflammatory processes. MicroRNAs may be implicated in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), where immune function is impaired. The objective of this study was to determine the association between miRNAs in cytotoxic cells and CFS/ME. METHODS Natural Killer (NK) and CD8(+)T cells were preferentially isolated from peripheral blood mononuclear cells from all participants (CFS/ME, n=28; mean age=41.8±9.6 years and controls, n=28; mean age=45.3±11.7 years), via negative cell enrichment. Following total RNA extraction and subsequent synthesis of cDNA, reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) was used to determine the expression levels of nineteen miRNAs. RESULTS There was a significant reduction in the expression levels of miR-21, in both the NK and CD8(+)T cells in the CFS/ME sufferers. Additionally, the expression of miR-17-5p, miR-10a, miR-103, miR-152, miR-146a, miR-106, miR-223 and miR-191 was significantly decreased in NK cells of CFS/ME patients in comparison to the non-fatigued controls. LIMITATIONS The results from these investigations are not yet transferable into the clinical setting, further validatory studies are now required. CONCLUSIONS Collectively these miRNAs have been associated with apoptosis, cell cycle, development and immune function. Changes in miRNAs in cytotoxic cells may reduce the functional capacity of these cells and disrupt effective cytotoxic activity along with other immune functions in CFS/ME patients.

[1]  S T Holgate,et al.  Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome , 2005, Journal of Clinical Pathology.

[2]  N. Klimas,et al.  Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis , 2011, Journal of Translational Medicine.

[3]  Takeshi Kimura,et al.  MicroRNA-15b Modulates Cellular ATP Levels and Degenerates Mitochondria via Arl2 in Neonatal Rat Cardiac Myocytes* , 2009, The Journal of Biological Chemistry.

[4]  B. Rouse,et al.  Elucidating the protective and pathologic T cell species in the virus‐induced corneal immunoinflammatory condition herpetic stromal keratitis , 2005, Journal of leukocyte biology.

[5]  H. Allgayer,et al.  MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer , 2008, Oncogene.

[6]  Muller Fabbri,et al.  Modulation of miR-155 and miR-125b Levels following Lipopolysaccharide/TNF-α Stimulation and Their Possible Roles in Regulating the Response to Endotoxin Shock1 , 2007, The Journal of Immunology.

[7]  D. Staines,et al.  Gene Expression in Chronic Fatigue Syndrome , 2012 .

[8]  Paul Kellam,et al.  Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. , 2008, The Journal of infectious diseases.

[9]  N. Rajewsky,et al.  Regulation of the Germinal Center Response by MicroRNA-155 , 2007, Science.

[10]  C. Snell An International Perspective on the Future of Research in Chronic Fatigue Syndrome , 2012 .

[11]  Frank Speleman,et al.  A novel and universal method for microRNA RT-qPCR data normalization , 2009, Genome Biology.

[12]  E. Lin,et al.  A Bayesian approach to gene-gene and gene-environment interactions in chronic fatigue syndrome. , 2009, Pharmacogenomics.

[13]  David Baltimore,et al.  MicroRNA-155 is induced during the macrophage inflammatory response , 2007, Proceedings of the National Academy of Sciences.

[14]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[15]  Ian Hickie,et al.  The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study , 1994, Annals of Internal Medicine.

[16]  T. Kawai,et al.  Identification of Marker Genes for Differential Diagnosis of Chronic Fatigue Syndrome , 2022 .

[17]  H. Walczak,et al.  TRAIL: a multifunctional cytokine. , 2007, Frontiers in bioscience : a journal and virtual library.

[18]  M. Fletcher,et al.  Immunologic abnormalities in chronic fatigue syndrome , 1990, Journal of clinical microbiology.

[19]  Anton J. Enright,et al.  Requirement of bic/microRNA-155 for Normal Immune Function , 2007, Science.

[20]  J. Kerr Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis , 2008, Current rheumatology reports.

[21]  A. Sterner-Kock,et al.  Selection of Reference Genes for Quantitative Real-time PCR Analysis in Canine Mammary Tumors Using the GeNorm Algorithm , 2006, Veterinary pathology.

[22]  Keiichiro Nishida,et al.  Expression of microRNA-146 in rheumatoid arthritis synovial tissue. , 2008, Arthritis and rheumatism.

[23]  C. Denkert,et al.  An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. , 2010, Cancer research.

[24]  Kaleb M. Pauley,et al.  miR-146a Is Critical for Endotoxin-induced Tolerance , 2009, The Journal of Biological Chemistry.

[25]  Xuan Pan,et al.  MicroRNA-21: A novel therapeutic target in human cancer , 2010, Cancer biology & therapy.

[26]  M. Kiriakidou,et al.  Clarifying mammalian RISC assembly in vitro , 2011, BMC Molecular Biology.

[27]  P. Sun,et al.  MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. , 2009, Biochemical and biophysical research communications.

[28]  S. Griffiths-Jones,et al.  miRBase: microRNA Sequences and Annotation , 2010, Current protocols in bioinformatics.

[29]  Hsien-Da Huang,et al.  microRNA: a master regulator of cellular processes for bioengineering systems. , 2010, Annual review of biomedical engineering.

[30]  Jung-Hwan Yoon,et al.  High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma. , 2009, Oncology reports.

[31]  B. Burke,et al.  Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes , 2007, Journal of Clinical Pathology.

[32]  Shizuo Akira,et al.  Signaling to NF-?B by Toll-like receptors , 2007 .

[33]  T. Han,et al.  Overexpression of miR-152 leads to reduced expression of human leukocyte antigen-G and increased natural killer cell mediated cytolysis in JEG-3 cells. , 2010, American journal of obstetrics and gynecology.

[34]  A. Liston,et al.  MicroRNA in the Adaptive Immune System, in Sickness and in Health , 2010, Journal of Clinical Immunology.

[35]  K. Jeang,et al.  Human T-cell leukemia virus type I at age 25: a progress report. , 2005, Cancer research.

[36]  Diego G. Silva,et al.  Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA , 2007, Nature.

[37]  J. Rehwinkel,et al.  MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. , 2006, Cold Spring Harbor symposia on quantitative biology.

[38]  Todd Wylie,et al.  Next-generation sequencing identifies the natural killer cell microRNA transcriptome. , 2010, Genome research.

[39]  R. Gutzmer,et al.  MicroRNA‐15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma , 2010, International journal of cancer.

[40]  A. Burny,et al.  Human natural Treg microRNA signature: Role of microRNA‐31 and microRNA‐21 in FOXP3 expression , 2009, European journal of immunology.

[41]  O. Baskurt,et al.  Immune and hemorheological changes in Chronic Fatigue Syndrome , 2010, Journal of Translational Medicine.

[42]  M. Fletcher,et al.  Chronic fatigue syndrome is associated with diminished intracellular perforin , 2005, Clinical and experimental immunology.

[43]  Qizhi Yao,et al.  Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real-Time PCR Analysis , 2009, World Journal of Surgery.

[44]  H. Weiner,et al.  Oral tolerance and TGF-beta-producing cells. , 2006, Inflammation & allergy drug targets.

[45]  J. Siegel,et al.  Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. , 1993, Journal of immunology.

[46]  H. Kung,et al.  MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. , 2009, Biochemical and biophysical research communications.

[47]  S. Hammond,et al.  An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells , 2000, Nature.

[48]  Pedro Romero,et al.  Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets , 2011, Journal of Translational Medicine.

[49]  W. Pearson,et al.  Current Protocols in Bioinformatics , 2002 .

[50]  Hua Zhao,et al.  A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. , 2008, Carcinogenesis.

[51]  Kedar S Vaidya,et al.  Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. , 2009, Cancer research.

[52]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[53]  Kevin Maher,et al.  Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26 , 2010, PloS one.

[54]  G. Kennedy,et al.  Is chronic fatigue syndrome associated with platelet activation? , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[55]  Subbaya Subramanian,et al.  MicroRNAs as gatekeepers of apoptosis , 2010, Journal of cellular physiology.

[56]  J. Dorfman,et al.  Acquisition of Ly49 Receptor Expression by Developing Natural Killer Cells , 1998, The Journal of experimental medicine.